N/A N=41 Damage Control for Duodenal and Combined Duodenal-Pancreatic Injuries
Injury of Duodenum · Pancreatic Injury
Primary: Duodenal-related Complications — 13; 11; 8; 19 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=73 Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients
Indigestion
Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants
Phase 3 N=427 Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin
Prevention
Primary: Time From Randomization to Occurrence of Gastric and/or Duodenal Ulcers up to Data Cut-off Date for Interim Analysis. — 1; 16; 1; 4 Participants — p=<0.001
Phase 3 N=50 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
Gastric Ulcer (GU) · Duodenal Ulcer (DU) · Anastomotic Ulcer (AU)
Primary: Disappearance of Heartburn at Week 8 by Patient Diaries — 2; 0; 0; 1 Participants
Phase 3 N=533 Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
Duodenal Ulcer
Primary: Percentage of Participants With Endoscopically Confirmed Healing of Duodenal Ulcers — 96.9; 96.5 percentage of participants
N/A N=105 Pancreatic Juice Diagnosis From Duodenum
Pancreatic Adenocarcinoma
Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001
Phase 4 N=87 Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole
Dyspepsia · Emergency · Pain
Primary: Pain Scores on the 100-millimeter Visual Analog Scale (VAS) at 1 Hour After Treatment — 17; 19 millimeter — p=0.6
N/A N=17 Comparison of Duodenal Stenting vs Transpyloric and Duodenal Stenting for Malignant Obstruction
Duodenal Obstruction
Primary: Number of Participants With Any Change (2 Point Increase or Decrease) in Symptoms From Baseline — 7; 6 Participants
N/A N=455 The Association With Peptic Ulcer Disease and Hepatic Vein Pressure Gradient
Cirrhosis · Chronic Liver Disease
Primary: The Association of HVPG and PUD in Patients With Liver Cirrhosis — 14.5; 15.3 mmHg
N/A N=3,183 Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"
Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis
Primary: Percentage of Participants With Gastric Ulcer Who Had One or More Adverse Drug Reactions — 1.00 Percentage of Participants
Phase 4 N=40 Ulcer Prevention Study in Post Gastric Bypass Patients
Marginal Ulcers
Primary: Number of Participants With Complaints, Specifically About Pain, Vomiting, Dyspepsia, and/or Dysphagia. — 17; 13 participants
Phase 2 N=247 Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Gastroduodenal Ulceration
Primary: Incidence of Gastroduodenal Ulcers — 28; 34 participants
Phase 3 N=343 Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID
Gastric Ulcer · Duodenal Ulcer · Rheumatoid Arthritis
Primary: Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period — 167; 112 Participants
Phase 3 N=366 Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs
Stomach Ulcer · Duodenal Ulcer
Primary: Number of Participants With Gastric Ulcer and/or Duodenal Ulcer — 15; 46 participants — p=<0.0001
Phase 2 N=165 Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
Peptic Ulcer
Primary: Recurrent Peptic Ulcer — 1; 9 participants
N/A N=220 Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm
Post-cholecystectomy Gastrointestinal Spasms
Primary: Percentage of "Responders" to Duspatalin® Therapy — 63.6; 36.4 percentage of participants
N/A N=101 Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
Peptic Ulcer
Primary: Number of Participants With Ulcer Recurrence — 1; 7 participants
Phase 4 N=301 Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
Stomach Ulcer
Primary: Gastric Ulcer Healing Rate (Number of Subjects Whose Gastric Ulcer Was Healed/Number of Subjects Evaluated x 100) at Week 8 — 70.13; 60.54 percentage of participants
Phase 4 N=178 A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers
Peptic Ulcer
Primary: Number of Participants in Whom Peptic Ulcer Was Healed — 66; 66 participants
N/A N=228 Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer
Peptic Ulcer
Primary: Number of Participants With Healed Peptic Ulcer — 106; 101 participants
Phase 2 N=20 Effect of Secretin in Functional Dyspepsia and Healthy Subjects
Dyspepsia · Healthy
Primary: Maximum Satiation — 892.5; 951.75; 655.5; 892.5 mL — p=0.12
N/A N=7 Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus
Peptic Ulcer
Primary: Number of Participants Completing Natural Orifice Translumenal Endoscopic Surgical (NOTES) Repair — 2; 1 participants
Phase 3 N=292 Functional Dyspepsia Treatment Trial
Dyspepsia and Other Specified Disorders of Function of Stomach
Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05
Phase 3 N=455 ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
Helicobacter Pylori Infection · Dyspepsia
Primary: Number of Participants With Eradication of H. Pylori — 191; 131 Participants — p=0.0001
Phase 3 N=50 A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer
Reflux Esophagitis · Gastric Ulcer · Duodenal Ulcer
Primary: Presence/Absence of Reflux Esophagitis Relapse — 0; 1; 7; 18 Participants
N/A N=14,965 Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms
Gastroesophageal Reflux Disease With Dyspepsia Symptoms
Primary: Subjective Symptom Improvement Rate — 75.7; 73.5; 68.6; 65.3 percentage of participants
Phase 3 N=519 Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
Gastric Ulcer
Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy — 7; 22 participants — p=0.005
Phase 4 N=9 C. Difficile and Ursodiol
Diarrhea
Primary: Percent of Patients With Return Toward a Normal Fecal Bile Acid Pattern — 100 percentage of participants
N/A N=235 Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage
UGI Bleeding · Ulcer or Variceal Hemorrhage · Stigmata of Recent Hemorrhage
Primary: 30 Day Rebleeding Rate — 20; 8; 17; 6 Participants
Phase 3 N=18 Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction)
Sphincter of Oddi Dysfunction
Primary: The Primary Outcome Measure Was a Patient Global Assessment of Change (PGIC) Scale. — 3.3 units on a scale